Startup
Information
Oniria Therapeutics, a company in the precision oncology field, is dedicated to solving cancer persistence by bringing to market ONR-001, a first-in-class drug for treating aggressive solid and liquid tumors that are unresponsive to current treatments. Our goal is to establish new, rational drug combinations or standalone treatments. Currently, we are characterizing our final candidate selected and preparing for the regulatory preclinical phase.
Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA).
Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA).
Key Information
- Growth Stage Series A
- Country Spain
- Founding Year 2021